Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Moneyclipon Feb 18, 2007 3:21pm
127 Views
Post# 12259538

RE: DD help - bfw

RE: DD help - bfwI for one am NOT a physician, rather an investor and have read through the patent information on a number of occasions in the past and drawn the conclusion, based on my limited knowledge of medicine that it appears that they have been sufficiently diligent in their patenting of their research. This said, I would appreciate you as a physician sharing with the board any observations, remarks or conclusions you may have after reviewing the previously posted patents. This would be in the interest of collaborative DD. GL to all
Bullboard Posts